Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Hefter

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Journal of Neurology|July 17, 2022
The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystoniaHarald Hefter, Beyza Ürer, Raphaela Brauns, et al.
European Neurology|July 8, 2010
Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson diseaseSara Hölscher, Barbara Leinweber, Harald Hefter, et al.
Journal of Rehabilitation Medicine. Clinical Communications|July 30, 2025
AN INTELLIGIBLE AI-DRIVEN DECISION SUPPORT SYSTEM FOR POSTSTROKE MOBILITY ASSESSMENTJin Cheng Liaw, Dominik Raab, Malte Weber, et al.
Frontiers in Neurology|March 19, 2020
Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of TreatmentJörg Wissel, Klemens Fheodoroff, Maurits Hoonhorst, et al.
Biomolecules|December 23, 2022
Pseudocholinesterase as a Biomarker for Untreated Wilson's DiseaseHarald Hefter, Max Arslan, Theodor S Kruschel, et al.
Journal of Clinical Medicine|July 29, 2023
Differences in the Time Course of Recovery from Brain and Liver Dysfunction in Conventional Long-Term Treatment of Wilson DiseaseHarald Hefter, Theodor S Kruschel, Max Novak, et al.
Plos One|November 21, 2012
Retinal neurodegeneration in Wilson's disease revealed by spectral domain optical coherence tomographyPhilipp Albrecht, Ann-Kristin Müller, Marius Ringelstein, et al.
Neurology|November 23, 2018
High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapyPhilipp Albrecht, Alexander Jansen, John-Ih Lee, et al.
Journal of Neurology|October 4, 2022
Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxinHarald Hefter, Dietmar Rosenthal, Alexander Jansen, et al.
Brain and Behavior|February 3, 2015
Increased volume and impaired function: the role of the basal ganglia in writer's crampKirsten E Zeuner, Arne Knutzen, Oliver Granert, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Journal of Neurology|July 17, 2022
The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystoniaHarald Hefter, Beyza Ürer, Raphaela Brauns, et al.
European Neurology|July 8, 2010
Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson diseaseSara Hölscher, Barbara Leinweber, Harald Hefter, et al.
Journal of Rehabilitation Medicine. Clinical Communications|July 30, 2025
AN INTELLIGIBLE AI-DRIVEN DECISION SUPPORT SYSTEM FOR POSTSTROKE MOBILITY ASSESSMENTJin Cheng Liaw, Dominik Raab, Malte Weber, et al.
Frontiers in Neurology|March 19, 2020
Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of TreatmentJörg Wissel, Klemens Fheodoroff, Maurits Hoonhorst, et al.
Biomolecules|December 23, 2022
Pseudocholinesterase as a Biomarker for Untreated Wilson's DiseaseHarald Hefter, Max Arslan, Theodor S Kruschel, et al.
Journal of Clinical Medicine|July 29, 2023
Differences in the Time Course of Recovery from Brain and Liver Dysfunction in Conventional Long-Term Treatment of Wilson DiseaseHarald Hefter, Theodor S Kruschel, Max Novak, et al.
Plos One|November 21, 2012
Retinal neurodegeneration in Wilson's disease revealed by spectral domain optical coherence tomographyPhilipp Albrecht, Ann-Kristin Müller, Marius Ringelstein, et al.
Neurology|November 23, 2018
High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapyPhilipp Albrecht, Alexander Jansen, John-Ih Lee, et al.
Journal of Neurology|October 4, 2022
Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxinHarald Hefter, Dietmar Rosenthal, Alexander Jansen, et al.
Brain and Behavior|February 3, 2015
Increased volume and impaired function: the role of the basal ganglia in writer's crampKirsten E Zeuner, Arne Knutzen, Oliver Granert, et al.
Pageof 8